Navigation Links
Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29
Date:10/25/2007

Presenters will Include World-Renowned RNase and RNA Researchers

SOMERSET, N.J., Oct. 25 /PRNewswire-FirstCall/ -- The RNA interference- like mechanics of ribonuclease (RNase) therapeutics will be the focus of scientific presentations in a Nov. 29 Webinar hosted by Alfacell Corporation (Nasdaq: ACEL).

Moderated by Kuslima Shogen, D.Sc., Alfacell's chairman and chief executive officer, and David Sidransky, M.D., Alfacell's scientific advisory board chairman, the Webinar will feature presentations about the basics of RNases, how RNases cleave RNA to interfere with the cell cycle, and the potential clinical applications for RNase therapeutics. The panel of presenters will be comprised of world-renowned RNase and RNA researchers, including:

-- Susanna Rybak, Ph.D., whose research has centered on the biology of

RNases for more than 25 years. Her laboratory at the National Cancer

Institute developed the groundwork for RNase-based therapeutics for

non-Hodgkin's lymphoma (NHL) and breast cancer. She has presented at

numerous national and international conferences and published her work

widely.

-- Jacob V. Maizel, Jr., Ph.D., whose distinguished career spans nearly

40 years in research on protein and RNA structure. From 1983 to 2005,

he was a laboratory chief at the National Cancer Institute. His

research focused on the use of high performance computing to discover

important structural features of RNA. His work in developing

graphical methods for understanding structure, organization and

evolution of genes led to the U.S. Public Health Service Superior

Award in 1982. He is also a featured speaker at industry seminars and

served on the editorial boards of several medical journals.

-- John J. Costanzi, M.D., is a principal investigator in the ONCONASE(R)

clinical trials program and internationally known in the field of

oncology. He is currently in the practice of oncology and hematology

in Austin, Texas. Formerly, he served as medical director of the

Thompson Cancer Survival Center in Knoxville, Tennessee, and as

professor of medicine and director of the cancer center for the

University of Texas Medical Branch in Galveston. He has received

numerous awards in the field of oncology and has authored over 140

papers, books and chapters in the area of clinical oncology.

The Webinar will begin at 8 a.m. EST on Nov. 29. To participate in the Webinar, click on the link posted on the Upcoming Events section of Alfacell's Web site at http://www.alfacell.com and enter 154905 for the room number. Please connect to the Webinar several minutes prior to the start time to ensure adequate time for any software download that may be necessary. The live event may also be accessed by dialing (877) 407-9205 (for U.S. callers) and (201) 689-8054 (for international callers). Questions may be asked over the telephone during the live event or e-mailed in advance to andreas.marathis@russopartnersllc.com. To access the replay, the Webinar will be available for 90 days on Alfacell's Web site at http://www.alfacell.com.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE(R), is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:

David Schull or Wendy Lau Andreas Marathovouniotis

Russo Partners Russo Partners

212-845-4271 212-845-4253

david.schull@russopartnersllc.com andreas.marathis@russopartnersllc.com

wendy.lau@russopartnersllc.com


'/>"/>
SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The mechanics of raising capital for your business
2. Protector RNase Inhibitor
3. Protector RNase Inhibitor Enhance the Protection of RNA against Degradation
4. RNase Protection Assay (RPA) Using DIG-Labeled RNA Probes
5. Inducing RNAi with siRNA Cocktails Generated by RNase III
6. Dicer vs. RNase III for Preparation of siRNA Cocktails
7. Combat RNase Contamination in the Lab
8. Measuring RNase Activity A Real-time Kinetic Analysis
9. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
10. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... YORK , June, 23, 2016  The Biodesign ... to envision new ways to harness living systems and ... Modern Art (MoMA) in New York City ... than 130 participating students, showcased projects at MoMA,s Celeste ... Paola Antonelli , MoMA,s senior curator of architecture ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... STACS DNA ... Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as a ... STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In further ...
Breaking Biology Technology:
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
(Date:6/3/2016)... 3, 2016 Das ... Nepal hat ein 44 ... geprägter Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, ... Produktion und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte ... Januar teilgenommen, aber Decatur wurde als konformste ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
Breaking Biology News(10 mins):